Literature DB >> 30950107

Statistical inference for data-adaptive doubly robust estimators with survival outcomes.

Iván Díaz1.   

Abstract

The consistency of doubly robust estimators relies on the consistent estimation of at least one of two nuisance regression parameters. In moderate-to-large dimensions, the use of flexible data-adaptive regression estimators may aid in achieving this consistency. However, n1/2 -consistency of doubly robust estimators is not guaranteed if one of the nuisance estimators is inconsistent. In this paper, we present a doubly robust estimator for survival analysis with the novel property that it converges to a Gaussian variable at an n1/2 -rate for a large class of data-adaptive estimators of the nuisance parameters, under the only assumption that at least one of them is consistently estimated at an n1/4 -rate. This result is achieved through the adaptation of recent ideas in semiparametric inference, which amount to (i) Gaussianizing (ie, making asymptotically linear) a drift term that arises in the asymptotic analysis of the doubly robust estimator and (ii) using cross-fitting to avoid entropy conditions on the nuisance estimators. We present the formula of the asymptotic variance of the estimator, which allows for the computation of doubly robust confidence intervals and p values. We illustrate the finite-sample properties of the estimator in simulation studies and demonstrate its use in a phase III clinical trial for estimating the effect of a novel therapy for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  CAN; cross-fitting; double robustness; targeted minimum loss-based estimation

Year:  2019        PMID: 30950107     DOI: 10.1002/sim.8156

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  1 in total

1.  Optimising precision and power by machine learning in randomised trials with ordinal and time-to-event outcomes with an application to COVID-19.

Authors:  Nicholas Williams; Michael Rosenblum; Iván Díaz
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2022-09-23       Impact factor: 2.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.